- Home
- DAWN vs XNCR Comparison
DAWN vs XNCR Comparison
Compare DAWN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- XNCR
- Stock Information
- Founded
- DAWN 2018
- XNCR 1997
- Country
- DAWN United States
- XNCR United States
- Employees
- DAWN N/A
- XNCR N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- DAWN Health Care
- XNCR Health Care
- Exchange
- DAWN Nasdaq
- XNCR Nasdaq
- Market Cap
- DAWN 624.8M
- XNCR 547.8M
- IPO Year
- DAWN 2021
- XNCR 2013
- Fundamental
- Price
- DAWN $7.19
- XNCR $8.51
- Analyst Decision
- DAWN Strong Buy
- XNCR Buy
- Analyst Count
- DAWN 7
- XNCR 10
- Target Price
- DAWN $27.86
- XNCR $23.33
- AVG Volume (30 Days)
- DAWN 1.1M
- XNCR 726.1K
- Earning Date
- DAWN 10-29-2025
- XNCR 11-05-2025
- Dividend Yield
- DAWN N/A
- XNCR N/A
- EPS Growth
- DAWN N/A
- XNCR N/A
- EPS
- DAWN N/A
- XNCR N/A
- Revenue
- DAWN $187,638,000.00
- XNCR $146,929,000.00
- Revenue This Year
- DAWN $12.56
- XNCR $22.06
- Revenue Next Year
- DAWN $48.02
- XNCR N/A
- P/E Ratio
- DAWN N/A
- XNCR N/A
- Revenue Growth
- DAWN 2190.50
- XNCR N/A
- 52 Week Low
- DAWN $5.64
- XNCR $6.92
- 52 Week High
- DAWN $16.76
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- DAWN 52.01
- XNCR 57.20
- Support Level
- DAWN $7.18
- XNCR $8.25
- Resistance Level
- DAWN $7.58
- XNCR $8.73
- Average True Range (ATR)
- DAWN 0.27
- XNCR 0.37
- MACD
- DAWN -0.03
- XNCR 0.07
- Stochastic Oscillator
- DAWN 33.92
- XNCR 75.22
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.